{"DataElement":{"publicId":"5119471","version":"1","preferredName":"Abnormal Trial Eligibility Determination Comorbid Condition Name","preferredDefinition":"Name of an abnormal condition or comorbidity used to determine clinical trial eligibility.","longName":"ABNL_ELIG_COMBID_NM","context":"DCP","contextVersion":"1","DataElementConcept":{"publicId":"5119470","version":"1","preferredName":"Abnormal Trial Eligibility Determination Comorbidity","preferredDefinition":"Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm._Criteria to determine eligibility of patients for medical care programs and services._Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research._The coexistence of two or more disease processes.","longName":"5040173v1.0:2829778v1.0","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"5040173","version":"1","preferredName":"Abnormal Clinical Study Eligibility Determination","preferredDefinition":"Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm.:Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.:Criteria to determine eligibility of patients for medical care programs and services.","longName":"C25401:C15206:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abnormal","conceptCode":"C25401","definition":"Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Clinical Study","conceptCode":"C15206","definition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2342E5DE-34E1-4A40-E050-BB89AD433BA0","latestVersionIndicator":"Yes","beginDate":"2015-10-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-29","modifiedBy":"ONEDATA","dateModified":"2015-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2829778","version":"1","preferredName":"Comorbidity","preferredDefinition":"The coexistence of two or more disease processes.","longName":"C16457","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Comorbidity","conceptCode":"C16457","definition":"The coexistence of two or more disease processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"616AAE12-2597-09E1-E040-BB89AD43623A","latestVersionIndicator":"Yes","beginDate":"2009-01-26","endDate":null,"createdBy":"CZECHS","dateCreated":"2009-01-26","modifiedBy":"ONEDATA","dateModified":"2009-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B5BD529-8ABA-231B-E050-BB89AD430541","latestVersionIndicator":"Yes","beginDate":"2016-02-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-09","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2970663","version":"1","preferredName":"Comorbidity Condition Name","preferredDefinition":"The coexistence of two or more disease processes._A state of being, such as a state of health._The words or language units by which a thing is known.","longName":"COMORB_NM","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Coronary Artery Disease","valueDescription":"Coronary Disease","ValueMeaning":{"publicId":"2760269","version":"1","preferredName":"Coronary Disease","longName":"2760269","preferredDefinition":"An imbalance between myocardial functional requirements and the capacity of the coronary vessels to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Coronary Artery Disease","conceptCode":"C26732","definition":"Narrowing of the coronary arteries due to fatty deposits inside the arterial walls. The diagnostic criteria may include documented history of any of the following: documented coronary artery stenosis greater than or equal to 50% (by cardiac catheterization or other modality of direct imaging of the coronary arteries); previous coronary artery bypass surgery (CABG); previous percutaneous coronary intervention (PCI); previous myocardial infarction. (ACC)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FF5CBC6-3CA7-1060-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-06-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B026653-DA7D-DD0C-E040-BB89AD4324C4","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-18","modifiedBy":"ONEDATA","dateModified":"2009-12-18","deletedIndicator":"No"},{"value":"Hypercholesterolemia","valueDescription":"Hypercholesterolemia","ValueMeaning":{"publicId":"2751387","version":"1","preferredName":"Hypercholesterolemia","longName":"2751387","preferredDefinition":"Hypercholesterolemia; the presence of an abnormal amount of cholesterol in the cells and plasma of the blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypercholesterolemia","conceptCode":"C37967","definition":"A laboratory test result indicating an increased amount of cholesterol in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4DC907AE-08A4-716C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B026653-DA88-DD0C-E040-BB89AD4324C4","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-18","modifiedBy":"ONEDATA","dateModified":"2009-12-18","deletedIndicator":"No"},{"value":"Hypertension","valueDescription":"Hypertension","ValueMeaning":{"publicId":"2562555","version":"1","preferredName":"Hypertension","longName":"2562555","preferredDefinition":"Abnormally high blood pressure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypertension","conceptCode":"C3117","definition":"Blood pressure that is abnormally high.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C168-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-04","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-10-04","modifiedBy":"ZHANGW","dateModified":"2008-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B026653-DA93-DD0C-E040-BB89AD4324C4","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-18","modifiedBy":"ONEDATA","dateModified":"2009-12-18","deletedIndicator":"No"},{"value":"Peripheral Vascular Disease","valueDescription":"Peripheral Vascular Disease","ValueMeaning":{"publicId":"2970666","version":"1","preferredName":"Peripheral Vascular Disease","longName":"2970666v1.00","preferredDefinition":"Any disorder affecting blood flow through the veins or arteries outside of the heart.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peripheral Vascular Disorder","conceptCode":"C35136","definition":"Any disorder affecting blood flow through the veins or arteries outside of the heart.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B026653-DAA1-DD0C-E040-BB89AD4324C4","latestVersionIndicator":"Yes","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-18","modifiedBy":"KUMMEROA","dateModified":"2023-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B026653-DABA-DD0C-E040-BB89AD4324C4","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-18","modifiedBy":"ONEDATA","dateModified":"2009-12-18","deletedIndicator":"No"},{"value":"GERD","valueDescription":"Gastroesophageal Reflux Disease","ValueMeaning":{"publicId":"2944845","version":"1","preferredName":"Gastroesophageal Reflux Disease","longName":"2944845","preferredDefinition":"A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastroesophageal Reflux Disease","conceptCode":"C26781","definition":"A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74450F48-355A-F0DB-E040-BB89AD437C48","latestVersionIndicator":"Yes","beginDate":"2009-09-23","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C08420A-B1D5-2A47-E040-BB89AD433D97","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"ONEDATA","dateModified":"2009-12-31","deletedIndicator":"No"},{"value":"MAI","valueDescription":"Mycobacterium Avium Intracellulare","ValueMeaning":{"publicId":"2975593","version":"1","preferredName":"Mycobacterium Avium Intracellulare","longName":"2975593","preferredDefinition":"Lymph node infection by Mycobacterium avium or Mycobacterium intracellulare. It most often affects children and usually presents with cervical lymph node enlargement. It generally follows a benign clinical course.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycobacterium Avium Complex Lymphadenitis","conceptCode":"C27314","definition":"Lymph node infection by Mycobacterium avium or Mycobacterium intracellulare. It most often affects children and usually presents with cervical lymph node enlargement. It generally follows a benign clinical course.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C08420A-B1E3-2A47-E040-BB89AD433D97","latestVersionIndicator":"Yes","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C08420A-B1FC-2A47-E040-BB89AD433D97","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"ONEDATA","dateModified":"2009-12-31","deletedIndicator":"No"},{"value":"Asthma","valueDescription":"Asthma","ValueMeaning":{"publicId":"2975594","version":"1","preferredName":"Asthma","longName":"2975594","preferredDefinition":"A chronic respiratory disease manifested as difficulty breathing due to the narrowing of bronchial passageways.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Asthma","conceptCode":"C28397","definition":"A chronic respiratory disease manifested as difficulty breathing due to the narrowing of bronchial passageways.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C08420A-B206-2A47-E040-BB89AD433D97","latestVersionIndicator":"Yes","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C08420A-B21F-2A47-E040-BB89AD433D97","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"ONEDATA","dateModified":"2009-12-31","deletedIndicator":"No"},{"value":"Pulmonary Fibrosis","valueDescription":"Pulmonary Fibrosis","ValueMeaning":{"publicId":"2946061","version":"1","preferredName":"Pulmonary Fibrosis","longName":"2946061","preferredDefinition":"Chronic progressive interstitial lung disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure, or right heart failure. Causes include chronic inflammatory processes, exposure to environmental irritants, radiation therapy, autoimmune disorders, certain drugs, or it may be idiopathic (no identifiable cause).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pulmonary Fibrosis","conceptCode":"C26869","definition":"Chronic progressive interstitial lung disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure, or right heart failure. Causes include chronic inflammatory processes, exposure to environmental irritants, radiation therapy, autoimmune disorders, certain drugs, or it may be idiopathic (no identifiable cause).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746AE5AE-64F0-370C-E040-BB89AD4351E3","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C08420A-B233-2A47-E040-BB89AD433D97","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"ONEDATA","dateModified":"2009-12-31","deletedIndicator":"No"},{"value":"Kidney Disease","valueDescription":"Renal Disorder","ValueMeaning":{"publicId":"2975595","version":"1","preferredName":"Renal Disorder","longName":"2975595","preferredDefinition":"A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kidney Disorder","conceptCode":"C3149","definition":"A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C084539-0EDE-6AD0-E040-BB89AD43189B","latestVersionIndicator":"Yes","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C084539-0EF7-6AD0-E040-BB89AD43189B","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"ONEDATA","dateModified":"2009-12-31","deletedIndicator":"No"},{"value":"Hepatitis C Infection","valueDescription":"Hepatitis C","ValueMeaning":{"publicId":"2975596","version":"1","preferredName":"Hepatitis C","longName":"2975596","preferredDefinition":"An RNA virus, causes non-A and non-B Hepatitis and liver cancer","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatitis C Infection","conceptCode":"C3098","definition":"A viral infection caused by the hepatitis C virus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C084539-0F01-6AD0-E040-BB89AD43189B","latestVersionIndicator":"Yes","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C084539-0F19-6AD0-E040-BB89AD43189B","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"ONEDATA","dateModified":"2009-12-31","deletedIndicator":"No"},{"value":"Hepatitis B Infection","valueDescription":"Hepatitis B","ValueMeaning":{"publicId":"2946400","version":"1","preferredName":"Hepatitis B","longName":"2946400","preferredDefinition":"A viral hepatitis caused by the Hepatitis B virus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatitis B Infection","conceptCode":"C3097","definition":"A viral infection caused by the hepatitis B virus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7472988E-D1A5-00A0-E040-BB89AD433FCF","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C084539-0F2E-6AD0-E040-BB89AD43189B","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"ONEDATA","dateModified":"2009-12-31","deletedIndicator":"No"},{"value":"Blood Clots","valueDescription":"Blood Clot","ValueMeaning":{"publicId":"2757885","version":"1","preferredName":"Blood Clot","longName":"2757885","preferredDefinition":"An aggregation of blood factors, primarily platelets and fibrin with entrapment of cellular elements, frequently causing vascular obstruction at the point of its formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blood Clot","conceptCode":"C27083","definition":"An aggregation of blood factors, primarily platelets and fibrin with entrapment of cellular elements, frequently causing vascular obstruction at the point of its formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F3F8B84-D608-3BC8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-06-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C084539-0F42-6AD0-E040-BB89AD43189B","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"ONEDATA","dateModified":"2009-12-31","deletedIndicator":"No"},{"value":"Sarcoidosis","valueDescription":"Sarcoidosis","ValueMeaning":{"publicId":"2975598","version":"1","preferredName":"Sarcoidosis","longName":"2975598","preferredDefinition":"inflammatory disease characterized by small lumps or granulomas in lymph nodes and other organs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcoidosis","conceptCode":"C34995","definition":"An idiopathic inflammatory disorder characterized by the formation of non-necrotizing epithelioid granulomas which contain giant cells. It usually affects the lungs, lymph nodes, liver, and skin. Cardiac involvement is also possible.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C084539-0F50-6AD0-E040-BB89AD43189B","latestVersionIndicator":"Yes","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C084539-0F69-6AD0-E040-BB89AD43189B","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"ONEDATA","dateModified":"2009-12-31","deletedIndicator":"No"},{"value":"Myocardial Infarction","valueDescription":"Myocardial Infarction","ValueMeaning":{"publicId":"2570461","version":"1","preferredName":"Myocardial Infarction","longName":"2570461","preferredDefinition":"Gross necrosis of the myocardium, as a result of interruption of the blood supply to the area, as in coronary thrombosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myocardial Infarction","conceptCode":"C27996","definition":"Gross necrosis of the myocardium, as a result of interruption of the blood supply to the area, as in coronary thrombosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E04A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"MAESKEB","dateModified":"2022-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C084539-0F73-6AD0-E040-BB89AD43189B","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"ONEDATA","dateModified":"2009-12-31","deletedIndicator":"No"},{"value":"Allergies","valueDescription":"Allergies","ValueMeaning":{"publicId":"2944512","version":"1","preferredName":"Allergies","longName":"2944512","preferredDefinition":"An immune response that occurs following exposure to an innocuous antigen, but that does not require the presence of preformed antibodies to the antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypersensitivity","conceptCode":"C3114","definition":"An immune response that occurs following exposure to an innocuous antigen, but that does not require the presence of preformed antibodies to the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"743C896C-2006-79F1-E040-BB89AD4359CF","latestVersionIndicator":"Yes","beginDate":"2009-09-23","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B03BA39-F954-A853-E040-BB89AD433913","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-18","modifiedBy":"ONEDATA","dateModified":"2009-12-18","deletedIndicator":"No"},{"value":"Calcium Channel Blockers","valueDescription":"Calcium Channel Blocker","ValueMeaning":{"publicId":"2970708","version":"1","preferredName":"Calcium Channel Blocker","longName":"2970708","preferredDefinition":"A class of drugs that act by selective inhibition of calcium influx through cell membranes or on the release and binding of calcium in intracellular pools. Since they are inducers of vascular and other smooth muscle relaxation, they are used in the drug therapy of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcium Channel Blocker","conceptCode":"C333","definition":"A pharmaceutical agent that inhibits the movement of calcium across through calcium channels in the cell membrane, preventing or decreasing the amount of calcium able to enter the cell. These drugs are used for their chronotropic, antihypertensive and vasodilatory effects.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B03BA39-F962-A853-E040-BB89AD433913","latestVersionIndicator":"Yes","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-18","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B03BA39-F97B-A853-E040-BB89AD433913","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-18","modifiedBy":"ONEDATA","dateModified":"2009-12-18","deletedIndicator":"No"},{"value":"Renal Insufficiency","valueDescription":"Renal Insufficiency","ValueMeaning":{"publicId":"2970709","version":"1","preferredName":"Renal Insufficiency","longName":"2970709","preferredDefinition":"Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE. The most severe form is KIDNEY FAILURE. Renal function may deteriorate slowly (RENAL INSUFFICIENCY, CHRONIC) or precipitously (RENAL INSUFFICIENCY, ACUTE).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Renal Insufficiency","conceptCode":"C1565489","definition":"Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE. The most severe form is KIDNEY FAILURE. Renal function may deteriorate slowly (RENAL INSUFFICIENCY, CHRONIC) or precipitously (RENAL INSUFFICIENCY, ACUTE).","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B03BA39-F985-A853-E040-BB89AD433913","latestVersionIndicator":"Yes","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B03BA39-F99E-A853-E040-BB89AD433913","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-18","modifiedBy":"ONEDATA","dateModified":"2009-12-18","deletedIndicator":"No"},{"value":"Diabetes","valueDescription":"Diabetes Mellitus","ValueMeaning":{"publicId":"2573558","version":"1","preferredName":"Diabetes Mellitus","longName":"2573558","preferredDefinition":"(dye-a-BEE-teez) A disease in which the body does not properly control the amount of sugar in the blood. As a result, the level of sugar in the blood is too high. This disease occurs when the body does not produce enough insulin or does not use it properly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diabetes Mellitus","conceptCode":"C2985","definition":"A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EC63-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"CZECHS","dateModified":"2008-06-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B03BA39-F9A8-A853-E040-BB89AD433913","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-18","modifiedBy":"ONEDATA","dateModified":"2009-12-18","deletedIndicator":"No"},{"value":"Cerebrovascular Disease","valueDescription":"Cerebrovascular Disorder","ValueMeaning":{"publicId":"2970710","version":"1","preferredName":"Cerebrovascular Disorder","longName":"2970710","preferredDefinition":"A broad category of disorders characterized by impairment of blood flow in the arteries and veins which supply the brain. These include CEREBRAL INFARCTION; BRAIN ISCHEMIA; HYPOXIA, BRAIN; INTRACRANIAL EMBOLISM AND THROMBOSIS; INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; and VASCULITIS, CENTRAL NERVOUS SYSTEM. In common usage, the term cerebrovascular disorders is not limited to conditions that affect the cerebrum, but refers to vascular disorders of the entire brain including the DIENCEPHALON; BRAIN STEM; and CEREBELLUM.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cerebrovascular Disorder","conceptCode":"C2938","definition":"A disorder resulting from inadequate blood flow in the vessels that supply the brain. Representative examples include cerebrovascular ischemia, cerebral embolism, and cerebral infarction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B03BA39-F9B5-A853-E040-BB89AD433913","latestVersionIndicator":"Yes","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-18","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B03BA39-F9CE-A853-E040-BB89AD433913","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-18","modifiedBy":"ONEDATA","dateModified":"2009-12-18","deletedIndicator":"No"},{"value":"Tuberculosis","valueDescription":"Tuberculosis","ValueMeaning":{"publicId":"2971315","version":"1","preferredName":"Tuberculosis","longName":"2971315","preferredDefinition":"A chronic, recurrent infection caused by the bacterium Mycobacterium tuberculosis. Tuberculosis (TB) may affect almost any tissue or organ of the body with the lungs being the most common site of infection. The clinical stages of TB are primary or initial","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tuberculosis","conceptCode":"C3423","definition":"A chronic, recurrent infection caused by the bacterium Mycobacterium tuberculosis. Tuberculosis (TB) may affect almost any tissue or organ of the body with the lungs being the most common site of infection. The clinical stages of TB are primary or initial infection, latent or dormant infection, and recrudescent or adult-type TB. Ninety to 95% of primary TB infections may go unrecognized. Histopathologically, tissue lesions consist of granulomas which usually undergo central caseation necrosis. Local symptoms of TB vary according to the part affected; acute symptoms include hectic fever, sweats, and emaciation; serious complications include granulomatous erosion of pulmonary bronchi associated with hemoptysis. If untreated, progressive TB may be associated with a high degree of mortality. This infection is frequently observed in immunocompromised individuals with AIDS or a history of illicit IV drug use.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B198A4F-677C-7611-E040-BB89AD430A1F","latestVersionIndicator":"Yes","beginDate":"2009-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B198A4F-6795-7611-E040-BB89AD430A1F","beginDate":"2009-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-19","modifiedBy":"ONEDATA","dateModified":"2009-12-19","deletedIndicator":"No"},{"value":"Epilepsy","valueDescription":"Epilepsy","ValueMeaning":{"publicId":"2971317","version":"1","preferredName":"Epilepsy","longName":"2971317","preferredDefinition":"brain disorder characterized by recurring excessive neuronal discharge, exhibited by transient episodes of motor, sensory, or psychic dysfunction, with or without unconsciousness or convulsive movements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Seizure Disorder","conceptCode":"C3020","definition":"A brain disorder characterized by episodes of abnormally increased neuronal discharge resulting in transient episodes of sensory or motor neurological dysfunction, or psychic dysfunction. These episodes may or may not be associated with loss of consciousness or convulsions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B198A4F-67A2-7611-E040-BB89AD430A1F","latestVersionIndicator":"Yes","beginDate":"2009-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B198A4F-67BB-7611-E040-BB89AD430A1F","beginDate":"2009-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-19","modifiedBy":"ONEDATA","dateModified":"2009-12-19","deletedIndicator":"No"},{"value":"Hepatitis","valueDescription":"Hepatitis","ValueMeaning":{"publicId":"2567490","version":"1","preferredName":"Hepatitis","longName":"2567490","preferredDefinition":"Inflammation of the liver and liver disease involving degenerative or necrotic alterations of hepatocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatitis","conceptCode":"C3095","definition":"Inflammation of the liver; usually from a viral infection, but sometimes from toxic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D4AF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-19","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B198A4F-67C5-7611-E040-BB89AD430A1F","beginDate":"2009-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-19","modifiedBy":"ONEDATA","dateModified":"2009-12-19","deletedIndicator":"No"},{"value":"Liver Cirrhosis (Liver Disease)","valueDescription":"Cirrhosis","ValueMeaning":{"publicId":"2971318","version":"1","preferredName":"Cirrhosis","longName":"2971318","preferredDefinition":"A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cirrhosis","conceptCode":"C2951","definition":"A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B198A4F-67D0-7611-E040-BB89AD430A1F","latestVersionIndicator":"Yes","beginDate":"2009-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-19","modifiedBy":"MAESKEB","dateModified":"2022-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B198A4F-67E9-7611-E040-BB89AD430A1F","beginDate":"2009-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-19","modifiedBy":"ONEDATA","dateModified":"2009-12-19","deletedIndicator":"No"},{"value":"Anemia","valueDescription":"Anemia","ValueMeaning":{"publicId":"2746211","version":"1","preferredName":"Anemia","longName":"2746211","preferredDefinition":"A reduction in the number of red blood cells per cu mm, the amount of hemoglobin in 100 ml of blood, and the volume of packed red blood cells per 100 ml of blood. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anemia","conceptCode":"C2869","definition":"A reduction in the number of red blood cells, the amount of hemoglobin, and/or the volume of packed red blood cells. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C175B6C-FC71-2303-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B198A4F-67F3-7611-E040-BB89AD430A1F","beginDate":"2009-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-19","modifiedBy":"ONEDATA","dateModified":"2009-12-19","deletedIndicator":"No"},{"value":"Bronchitis","valueDescription":"Bronchitis","ValueMeaning":{"publicId":"2944459","version":"1","preferredName":"Bronchitis","longName":"2944459","preferredDefinition":"An acute or chronic inflammatory process affecting the bronchi.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bronchitis","conceptCode":"C2911","definition":"An acute or chronic inflammatory process affecting the bronchi.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74331C4B-D5AB-D41C-E040-BB89AD435AA5","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B198A4F-6808-7611-E040-BB89AD430A1F","beginDate":"2009-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-19","modifiedBy":"ONEDATA","dateModified":"2009-12-19","deletedIndicator":"No"},{"value":"Arrhythmia","valueDescription":"Arrhythmia","ValueMeaning":{"publicId":"2573555","version":"1","preferredName":"Arrhythmia","longName":"2573555","preferredDefinition":"Arrhythmia; an abnormal rate of muscle contractions in the heart.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arrhythmia","conceptCode":"C2881","definition":"Any variation from the normal rate or rhythm (which may include the origin of the impulse and/or its subsequent propagation) in the heart.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EC60-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"REEVESD","dateModified":"2006-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B198A4F-6813-7611-E040-BB89AD430A1F","beginDate":"2009-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-19","modifiedBy":"ONEDATA","dateModified":"2009-12-19","deletedIndicator":"No"},{"value":"Peptic Ulcer (Ulcer)","valueDescription":"Peptic Ulcer","ValueMeaning":{"publicId":"2573562","version":"1","preferredName":"Peptic Ulcer","longName":"2573562","preferredDefinition":"Ulcer that occurs in those portions of the alimentary tract which come into contact with gastric juice containing pepsin and acid. It occurs when the amount of acid and pepsin is sufficient to overcome the gastric mucosal barrier.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peptic Ulcer","conceptCode":"C3318","definition":"A mucosal erosion that occurs in the esophagus, stomach or duodenum. Symptoms can include abdominal pain, nausea and vomiting, and bleeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EC67-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B198A4F-6828-7611-E040-BB89AD430A1F","beginDate":"2009-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-19","modifiedBy":"ONEDATA","dateModified":"2009-12-19","deletedIndicator":"No"},{"value":"Rheumatologic Disease","valueDescription":"Rheumatologic Disorder","ValueMeaning":{"publicId":"2971319","version":"1","preferredName":"Rheumatologic Disorder","longName":"2971319","preferredDefinition":"Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rheumatologic Disorder","conceptCode":"C27204","definition":"Inflammatory and degenerative diseases of connective tissue structures, such as arthritis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B198A4F-6835-7611-E040-BB89AD430A1F","latestVersionIndicator":"Yes","beginDate":"2009-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-19","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B198A4F-684E-7611-E040-BB89AD430A1F","beginDate":"2009-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-19","modifiedBy":"ONEDATA","dateModified":"2009-12-19","deletedIndicator":"No"},{"value":"Obesity","valueDescription":"Obesity","ValueMeaning":{"publicId":"2945865","version":"1","preferredName":"Obesity","longName":"2945865","preferredDefinition":"Having a high amount of body fat (body mass index [BMI] of 30 or more).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Obesity","conceptCode":"C3283","definition":"Having a high amount of body fat (body mass index [BMI] of 30 or more).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74597246-17B3-6D19-E040-BB89AD431E08","latestVersionIndicator":"Yes","beginDate":"2009-09-24","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7B198A4F-6858-7611-E040-BB89AD430A1F","beginDate":"2009-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-19","modifiedBy":"ONEDATA","dateModified":"2009-12-19","deletedIndicator":"No"},{"value":"Smoking","valueDescription":"Smoking","ValueMeaning":{"publicId":"3187551","version":"1","preferredName":"Smoking","longName":"3187551","preferredDefinition":"The act of puffing and/or inhaling smoke from a lit cigarette, cigar, or pipe.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tobacco Smoking","conceptCode":"C17934","definition":"The act of puffing and/or inhaling smoke from a lit cigarette, cigar, or pipe.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9ADB9901-7B34-C15B-E040-BB89AD43580B","latestVersionIndicator":"Yes","beginDate":"2011-01-27","endDate":null,"createdBy":"UMLLOADER_GEM","dateCreated":"2011-01-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9A72D8B-F2CF-0839-E040-BB89AD437342","beginDate":"2012-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-23","modifiedBy":"ONEDATA","dateModified":"2012-02-23","deletedIndicator":"No"},{"value":"Heart disease","valueDescription":"Heart Disorder","ValueMeaning":{"publicId":"3181118","version":"1","preferredName":"Heart Disorder","longName":"3181118","preferredDefinition":"A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Heart Disorder","conceptCode":"C3079","definition":"A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"991CC1A7-5429-0D9B-E040-BB89AD4320EF","latestVersionIndicator":"Yes","beginDate":"2011-01-05","endDate":null,"createdBy":"LUY","dateCreated":"2011-01-05","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9A72D8B-F2E4-0839-E040-BB89AD437342","beginDate":"2012-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-23","modifiedBy":"ONEDATA","dateModified":"2012-02-23","deletedIndicator":"No"},{"value":"Inflammatory Bowel Disease","valueDescription":"Inflammatory Bowel Disease","ValueMeaning":{"publicId":"3305590","version":"1","preferredName":"Inflammatory Bowel Disease","longName":"3305590","preferredDefinition":"A spectrum of small and large bowel inflammatory diseases of unknown etiology. It includes Crohn's disease, ulcerative colitis, and colitis of indeterminate type. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inflammatory Bowel Disease","conceptCode":"C3138","definition":"A spectrum of small and large bowel inflammatory diseases of unknown etiology. It includes Crohn's disease, ulcerative colitis, and colitis of indeterminate type.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F4ADB4-3280-11AC-E040-BB89AD436AA7","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9A72D8B-F2F9-0839-E040-BB89AD437342","beginDate":"2012-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-23","modifiedBy":"ONEDATA","dateModified":"2012-02-23","deletedIndicator":"No"},{"value":"Hyperlipidemia","valueDescription":"Hyperlipidemia","ValueMeaning":{"publicId":"2751390","version":"1","preferredName":"Hyperlipidemia","longName":"2751390","preferredDefinition":"An excess of lipids in the blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyperlipidemia","conceptCode":"C34707","definition":"Elevated levels of lipids in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4DC907AE-0915-716C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9A72D8B-F304-0839-E040-BB89AD437342","beginDate":"2012-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-23","modifiedBy":"ONEDATA","dateModified":"2012-02-23","deletedIndicator":"No"},{"value":"COPD","valueDescription":"Chronic Obstructive Pulmonary Disease","ValueMeaning":{"publicId":"3385484","version":"1","preferredName":"Chronic Obstructive Pulmonary Disease","longName":"3385484","preferredDefinition":"A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Obstructive Pulmonary Disease","conceptCode":"C3199","definition":"A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9A72D8B-F30F-0839-E040-BB89AD437342","latestVersionIndicator":"Yes","beginDate":"2012-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B9A72D8B-F328-0839-E040-BB89AD437342","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-23","modifiedBy":"ONEDATA","dateModified":"2012-02-23","deletedIndicator":"No"},{"value":"Basal Cell Carcinoma","valueDescription":"Basal Cell Neoplasm","ValueMeaning":{"publicId":"3626733","version":"1","preferredName":"Basal Cell Neoplasm","longName":"3626733","preferredDefinition":"A neoplastic proliferation of basal cells in the epidermis (part of the skin) or other anatomic sites (most frequently the salivary glands).  The basal cell neoplastic proliferation in the epidermis results in basal cell carcinomas.  The basal cell neoplastic proliferation in the salivary glands can be benign, resulting in basal cell adenomas or malignant, resulting in basal cell adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Basal Cell Neoplasm","conceptCode":"C3784","definition":"A neoplastic proliferation of basal cells in the epidermis (part of the skin) or other anatomic sites (most frequently the salivary glands).  The basal cell neoplastic proliferation in the epidermis results in basal cell carcinomas.  The basal cell neoplastic proliferation in the salivary glands can be benign, resulting in basal cell adenomas or malignant, resulting in basal cell adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CEA36DD9-7089-2AFD-E040-BB89AD4344B7","latestVersionIndicator":"Yes","beginDate":"2012-11-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CEA36DD9-70A2-2AFD-E040-BB89AD4344B7","beginDate":"2012-11-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-16","modifiedBy":"ONEDATA","dateModified":"2012-11-16","deletedIndicator":"No"},{"value":"Cancer","valueDescription":"Carcinoma","ValueMeaning":{"publicId":"2935533","version":"1","preferredName":"Carcinoma","longName":"2935533","preferredDefinition":"A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71F88553-C4BB-17CC-E040-BB89AD43398B","latestVersionIndicator":"Yes","beginDate":"2009-08-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-08-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CEA36DD9-70B6-2AFD-E040-BB89AD4344B7","beginDate":"2012-11-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-16","modifiedBy":"ONEDATA","dateModified":"2012-11-16","deletedIndicator":"No"},{"value":"Atrial Fibrillation","valueDescription":"Atrial Fibrillation","ValueMeaning":{"publicId":"2760267","version":"1","preferredName":"Atrial Fibrillation","longName":"2760267","preferredDefinition":"A supraventricular arrhythmia characterized by uncoordinated atrial myocardium activation due to multiple reentry circuits with consequent deterioration of atrial mechanical function. Instead of intermittently contracting, the atria quiver continuously in a chaotic pattern, causing a totally irregular, often tachycardia ventricular rate. On the ECG it is described by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in size, shape, and timing, associated with an irregular, frequently rapid ventricular response when atrioventricular conduction is intact.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atrial Fibrillation","conceptCode":"C50466","definition":"A disorder characterized by an electrocardiographic finding of a supraventricular arrhythmia characterized by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in size, shape and timing and are accompanied by an irregular ventricular response. (CDISC)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FF5CBC6-3C42-1060-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-06-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D99CF626-D430-CD9D-E040-BB89AD4378D5","beginDate":"2013-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"ONEDATA","dateModified":"2013-04-05","deletedIndicator":"No"},{"value":"Connective Tissue Disorder","valueDescription":"Connective Tissue Disorder","ValueMeaning":{"publicId":"2593558","version":"1","preferredName":"Connective Tissue Disorder","longName":"2593558","preferredDefinition":"A non-neoplastic or neoplastic disorder that affects the connective tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Connective Tissue Disorder","conceptCode":"C26729","definition":"A non-neoplastic or neoplastic disorder that affects the connective tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BED146-B207-6CA9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"MAESKEB","dateModified":"2022-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D99CF626-D43B-CD9D-E040-BB89AD4378D5","beginDate":"2013-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"ONEDATA","dateModified":"2013-04-05","deletedIndicator":"No"},{"value":"Lupus","valueDescription":"Lupus Erythematosus","ValueMeaning":{"publicId":"3210816","version":"1","preferredName":"Lupus Erythematosus","longName":"3210816","preferredDefinition":"An autoimmune, connective tissue chronic inflammatory disorder affecting the skin, joints, kidneys, lungs, heart, and the peripheral blood cells. It is more commonly seen in women than men. Variants include discoid and systemic lupus erythematosus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lupus Erythematosus","conceptCode":"C27153","definition":"An autoimmune, connective tissue chronic inflammatory disorder affecting the skin, joints, kidneys, lungs, heart, and the peripheral blood cells. It is more commonly seen in women than men. Variants include discoid and systemic lupus erythematosus.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A4EC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D99CF626-D450-CD9D-E040-BB89AD4378D5","beginDate":"2013-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"ONEDATA","dateModified":"2013-04-05","deletedIndicator":"No"},{"value":"Ulcerative Colitis","valueDescription":"Ulcerative Colitis","ValueMeaning":{"publicId":"2577524","version":"1","preferredName":"Ulcerative Colitis","longName":"2577524","preferredDefinition":"Inflammatory disease of unknown cause which involves the mucosa of the colon. Onset may be acute and fulminant, and its course often continues chronically in an intermittent or continuous form. Diarrhea is a common symptom and bleeding an almost constant concomitant symptom.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ulcerative Colitis","conceptCode":"C2952","definition":"An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FBE1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-01-28","modifiedBy":"CZECHS","dateModified":"2008-06-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D99CF626-D45B-CD9D-E040-BB89AD4378D5","beginDate":"2013-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"ONEDATA","dateModified":"2013-04-05","deletedIndicator":"No"},{"value":"Psoriasis","valueDescription":"Psoriasis","ValueMeaning":{"publicId":"2567418","version":"1","preferredName":"Psoriasis","longName":"2567418","preferredDefinition":"A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Psoriasis","conceptCode":"C3346","definition":"An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D467-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D99CF626-D466-CD9D-E040-BB89AD4378D5","beginDate":"2013-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"ONEDATA","dateModified":"2013-04-05","deletedIndicator":"No"},{"value":"Arthritis","valueDescription":"Arthritis","ValueMeaning":{"publicId":"3292693","version":"1","preferredName":"Arthritis","longName":"3292693","preferredDefinition":"An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arthritis","conceptCode":"C2883","definition":"An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEA65AE0-D99F-3EBD-E040-BB89AD431EBC","latestVersionIndicator":"Yes","beginDate":"2011-10-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D99CF626-D47B-CD9D-E040-BB89AD4378D5","beginDate":"2013-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"ONEDATA","dateModified":"2013-04-05","deletedIndicator":"No"},{"value":"Congestive Heart Failure (CHF)","valueDescription":"Congestive heart failure","ValueMeaning":{"publicId":"2565944","version":"1","preferredName":"Congestive heart failure","longName":"2565944","preferredDefinition":"Failure of the heart to pump a sufficient amount of blood to meet the needs of the body tissues, resulting in tissue congestion and edema. Signs and symptoms include shortness of breath, pitting edema, enlarged tender liver, engorged neck veins, and pulmonary rales.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congestive Heart Failure","conceptCode":"C3080","definition":"Failure of the heart to pump a sufficient amount of blood to meet the needs of the body tissues, resulting in tissue congestion and edema. Signs and symptoms include shortness of breath, pitting edema, enlarged tender liver, engorged neck veins, and pulmonary rales.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CEA5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-05-19","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-05-19","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D99CF626-D490-CD9D-E040-BB89AD4378D5","beginDate":"2013-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"ONEDATA","dateModified":"2013-04-05","deletedIndicator":"No"},{"value":"Insulin controlled Diabetes","valueDescription":"Insulin-controlled Diabetes","ValueMeaning":{"publicId":"3718031","version":"1","preferredName":"Insulin-controlled Diabetes","longName":"3718031","preferredDefinition":"(IN-su-lin) A hormone made by the islet cells of the pancreas. Insulin controls the amount of sugar in the blood by moving it into the cells, where it can be used by the body for energy.: The act of directing or determining; regulation or maintenance of a function or action; a relation of constraint of one entity (thing or person or group) by another.: A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Insulin","conceptCode":"C2271","definition":"Insulin (51 aa, ~6 kDa) is encoded by the human INS gene. This protein is involved in the direct regulation of glucose metabolism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Control","conceptCode":"C61299","definition":"The act of directing or determining; regulation or maintenance of a function or action; a relation of constraint of one entity (thing or person or group) by another.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Diabetes Mellitus","conceptCode":"C2985","definition":"A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D99CF626-D49F-CD9D-E040-BB89AD4378D5","latestVersionIndicator":"Yes","beginDate":"2013-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D99CF626-D4B8-CD9D-E040-BB89AD4378D5","beginDate":"2013-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"ONEDATA","dateModified":"2013-04-05","deletedIndicator":"No"},{"value":"Diet controlled Diabetes","valueDescription":"Diet-controlled Diabetes","ValueMeaning":{"publicId":"3718032","version":"1","preferredName":"Diet-controlled Diabetes","longName":"3718032","preferredDefinition":"Regular course of eating and drinking adopted by a person or animal. This does not include DIET THERAPY, a specific diet prescribed in the treatment of a disease.: The act of directing or determining; regulation or maintenance of a function or action; a relation of constraint of one entity (thing or person or group) by another.: A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diet","conceptCode":"C15222","definition":"The customary allowance of food and drink taken by a person or an animal from day to day, particularly one especially planned to meet specific requirements of the individual, including or excluding certain items of food; a prescribed course of eating and drinking in which the amount and kind of food, as well as the times at which it is to be taken, are regulated for therapeutic purposes or selected with reference to a particular state of health.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Control","conceptCode":"C61299","definition":"The act of directing or determining; regulation or maintenance of a function or action; a relation of constraint of one entity (thing or person or group) by another.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Diabetes Mellitus","conceptCode":"C2985","definition":"A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D99CF626-D4C6-CD9D-E040-BB89AD4378D5","latestVersionIndicator":"Yes","beginDate":"2013-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D99CF626-D4DF-CD9D-E040-BB89AD4378D5","beginDate":"2013-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"ONEDATA","dateModified":"2013-04-05","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D99CF626-D4E9-CD9D-E040-BB89AD4378D5","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-05","modifiedBy":"ONEDATA","dateModified":"2013-04-05","deletedIndicator":"No"},{"value":"Diabetic Neuropathy","valueDescription":"Diabetic Neuropathy","ValueMeaning":{"publicId":"5040588","version":"1","preferredName":"Diabetic Neuropathy","longName":"5040588","preferredDefinition":"Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diabetic Neuropathy","conceptCode":"C26748","definition":"A chronic, pathological complication associated with diabetes mellitus, where nerve damages are incurred due to diabetic microvascular injury involving small blood vessels that supply these nerves, resulting in peripheral and/or autonomic nerve dysfunction.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"235310F3-A300-CA55-E050-BB89AD432272","latestVersionIndicator":"Yes","beginDate":"2015-10-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"235310F3-A319-CA55-E050-BB89AD432272","beginDate":"2015-10-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-30","modifiedBy":"ONEDATA","dateModified":"2015-10-30","deletedIndicator":"No"},{"value":"Other cancer within 5 years","valueDescription":"Past 5 Year Malignant Neoplasm","ValueMeaning":{"publicId":"5040590","version":"1","preferredName":"Past 5 Year Malignant Neoplasm","longName":"5040590","preferredDefinition":"Before the present time.: A number with no fractional part, including the negative and positive numbers as well as zero.::5: A period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period.: A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Past","conceptCode":"C25609","definition":"Before the present time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Year","conceptCode":"C29848","definition":"A period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"235310F3-A350-CA55-E050-BB89AD432272","latestVersionIndicator":"Yes","beginDate":"2015-10-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-30","modifiedBy":"KUMMEROA","dateModified":"2021-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"235310F3-A369-CA55-E050-BB89AD432272","beginDate":"2015-10-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-30","modifiedBy":"ONEDATA","dateModified":"2015-10-30","deletedIndicator":"No"},{"value":"Other nonmalignant systemic disease","valueDescription":"Other Nonmalignant Systemic Disease or Disorder","ValueMeaning":{"publicId":"5040589","version":"1","preferredName":"Other Nonmalignant Systemic Disease or Disorder","longName":"5040589","preferredDefinition":"Different than the one(s) previously specified or mentioned.: For neoplasms, a neoplastic process that, at the time of the pathologic diagnosis, does not show evidence of tissue infiltration and may or may not show evidence of atypical morphologic features (e.g., cellular atypia, formation of complex structures, cellular pseudostratification, and increased mitotic activity).  This term encompasses benign neoplastic processes, neoplastic processes with dysplastic features, and borderline processes.  The former do not metastasize and the latter two are associated with a future risk of stromal invasion and metastasis. For other conditions, a process that is not seriously resistant to treatment or dangerous to health.: Affecting the entire body.: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Non-Malignant","conceptCode":"C25588","definition":"For neoplasms, a neoplastic process that, at the time of the pathologic diagnosis, does not show evidence of tissue infiltration and may or may not show evidence of atypical morphologic features (e.g., cellular atypia, formation of complex structures, cellular pseudostratification, and increased mitotic activity).  This term encompasses benign neoplastic processes, neoplastic processes with dysplastic features, and borderline processes.  The former do not metastasize and the latter two are associated with a future risk of stromal invasion and metastasis. For other conditions, a process that is not seriously resistant to treatment or dangerous to health.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Systemic","conceptCode":"C13310","definition":"Affecting an entire system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"235310F3-A328-CA55-E050-BB89AD432272","latestVersionIndicator":"Yes","beginDate":"2015-10-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-30","modifiedBy":"KUMMEROA","dateModified":"2021-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2ACEE896-CBC9-F719-E050-BB89AD430485","beginDate":"2015-10-30","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-02-02","modifiedBy":"ONEDATA","dateModified":"2016-02-02","deletedIndicator":"No"},{"value":"None","valueDescription":"None","ValueMeaning":{"publicId":"2577064","version":"1","preferredName":"None","longName":"2577064","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2E44292C-AEDE-4BBD-E050-BB89AD43738D","beginDate":"2016-03-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-03-17","modifiedBy":"ONEDATA","dateModified":"2016-03-17","deletedIndicator":"No"},{"value":"Cataracts","valueDescription":"Cataract","ValueMeaning":{"publicId":"3123331","version":"1","preferredName":"Cataract","longName":"3123331","preferredDefinition":"A disorder characterized by partial or complete opacity of the crystalline lens of one or both eyes. This results in a decrease in visual acuity and eventual blindness if untreated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cataract","conceptCode":"E10350","definition":"A disorder characterized by partial or complete opacity of the crystalline lens of one or both eyes. This results in a decrease in visual acuity and eventual blindness if untreated.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BBEC77A-9741-3404-E040-BB89AD43456A","latestVersionIndicator":"Yes","beginDate":"2010-07-19","endDate":null,"createdBy":"CURTIST","dateCreated":"2010-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AECAE5-BC01-28A7-E053-F662850AD609","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Stroke","valueDescription":"Cerebrovascular Accident","ValueMeaning":{"publicId":"4733294","version":"1","preferredName":"Cerebrovascular Accident","longName":"4733294","preferredDefinition":"A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stroke","conceptCode":"C3390","definition":"A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"107BC70C-A141-B0D0-E050-BB89AD432FE8","latestVersionIndicator":"Yes","beginDate":"2015-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-EB5A-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Renal failure (requiring dialysis)","valueDescription":"Renal Failure with dialysis","ValueMeaning":{"publicId":"5621707","version":"1","preferredName":"Renal Failure with dialysis","longName":"5621707","preferredDefinition":"The process of cleansing the blood when the kidneys are not able to filter the blood.: An acute or chronic condition that is characterized by the inability of the kidneys to adequately filter the blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dialysis","conceptCode":"C15221","definition":"A procedure to remove toxic substances from the blood that is used in patients with end-stage chronic kidney disease or acute kidney failure. This includes hemodialysis and peritoneal dialysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Renal Failure","conceptCode":"C4376","definition":"An acute or chronic condition that is characterized by the inability of the kidneys to adequately filter the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AE87ED-EB68-6297-E053-F662850A80DB","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-EB81-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Other pulmonary complications","valueDescription":"Other Pulmonary Complication","ValueMeaning":{"publicId":"5621708","version":"1","preferredName":"Other Pulmonary Complication","longName":"5621708","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Having to do with the lungs.: Any disease or disorder that occurs during the course of, or because of, another disease, treatment, or procedure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pulmonary","conceptCode":"C13304","definition":"Relating to the lungs as the intended site of administration, where the pharmaceutical product is administered, usually by inhalation, for local action in the lower respiratory tract or for systemic action after absorption via the lower respiratory tract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complication","conceptCode":"C2959","definition":"Any disease or disorder that occurs during the course of, or because of, another disease, treatment, or procedure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AE87ED-EB8F-6297-E053-F662850A80DB","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-EBA8-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"HUS/TTP","valueDescription":"Hemolytic Uremic Syndrome or Thrombotic Thrombocytopenic Purpura","ValueMeaning":{"publicId":"5621710","version":"1","preferredName":"Hemolytic Uremic Syndrome or Thrombotic Thrombocytopenic Purpura","longName":"5621710","preferredDefinition":"Acute kidney injury associated with microangiopathic hemolytic anemia and thrombocytopenia.: A coagulation disorder characterized by extensive formation of thrombi in small blood vessels throughout the body due to low levels of ADAMTS13 protein, and resulting in consumption of circulating platelets, which is characterized by thrombocytopenia, anemia, neurologic changes, and sometimes fever and renal dysfunction.: The coexistence of two or more disease processes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemolytic Uremic Syndrome","conceptCode":"C75545","definition":"Acute kidney injury associated with microangiopathic hemolytic anemia and thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Thrombotic Thrombocytopenic Purpura","conceptCode":"C78797","definition":"A coagulation disorder characterized by extensive formation of thrombi in small blood vessels throughout the body due to low levels of ADAMTS13 protein, and resulting in consumption of circulating platelets, which is characterized by thrombocytopenia, anemia, neurologic changes, and sometimes fever and renal dysfunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Comorbidity","conceptCode":"C16457","definition":"The coexistence of two or more disease processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AE87ED-EBDB-6297-E053-F662850A80DB","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-EBF4-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Pregnancy in patient or partner","valueDescription":"Pregnancy","ValueMeaning":{"publicId":"5621711","version":"1","preferredName":"Pregnancy","longName":"5621711","preferredDefinition":"The state or condition of having a developing embryo or fetus in the body (uterus), after union of an ovum and spermatozoon, during the period from conception to birth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pregnancy","conceptCode":"C25742","definition":"The state or condition of having a developing embryo or fetus in the body (uterus), after union of an ovum and spermatozoon, during the period from conception to birth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AE87ED-EBFE-6297-E053-F662850A80DB","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-EC17-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Osteoporosis or Osteopenia","valueDescription":"Osteoporosis or Osteopenia","ValueMeaning":{"publicId":"5621712","version":"1","preferredName":"Osteoporosis or Osteopenia","longName":"5621712","preferredDefinition":"A condition of reduced bone mass, with decreased cortical thickness and a decrease in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence. Osteoporosis is classified as primary (Type 1, postmenopausal osteoporosis; Type 2, age-associated osteoporosis; and idiopathic, which can affect juveniles, premenopausal women, and middle-aged men) and secondary osteoporosis (which results from an identifiable cause of bone mass loss).: Decreased calcification or density of bone tissue.: The coexistence of two or more disease processes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteoporosis","conceptCode":"C3298","definition":"A condition of reduced bone mass, with decreased cortical thickness and a decrease in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence. Osteoporosis is classified as primary (Type 1, postmenopausal osteoporosis; Type 2, age-associated osteoporosis; and idiopathic, which can affect juveniles, premenopausal women, and middle-aged men) and secondary osteoporosis (which results from an identifiable cause of bone mass loss).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Osteopenia","conceptCode":"C50910","definition":"Decreased calcification or density of bone tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Comorbidity","conceptCode":"C16457","definition":"The coexistence of two or more disease processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AE87ED-EC3A-6297-E053-F662850A80DB","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-EC53-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Organ transplant (site)","valueDescription":"Organ Transplantation","ValueMeaning":{"publicId":"5621713","version":"1","preferredName":"Organ Transplantation","longName":"5621713","preferredDefinition":"The transfer of an organ, organ part, or tissue from one body to another, for the purpose of replacing the recipient's damaged or failing organ with a working one from the donor. Donors can be living, or cadaveric (dead).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Organ Transplantation","conceptCode":"C15289","definition":"The transfer of an organ, organ part, or tissue from one body to another, for the purpose of replacing the recipient's damaged or failing organ with a working one from the donor. Donors can be living, or cadaveric (dead).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AE87ED-EC5D-6297-E053-F662850A80DB","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-EC76-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Liver toxicity (non-infectious)","valueDescription":"Liver Toxicity","ValueMeaning":{"publicId":"5621714","version":"1","preferredName":"Liver Toxicity","longName":"5621714","preferredDefinition":"A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.: The finding of bodily harm due to the poisonous effects of something.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liver","conceptCode":"C12392","definition":"A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Toxicity","conceptCode":"C27990","definition":"The finding of bodily harm due to the poisonous effects of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AE87ED-EC83-6297-E053-F662850A80DB","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-EC9C-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Joint replacement","valueDescription":"Joint replacement","ValueMeaning":{"publicId":"5621715","version":"1","preferredName":"Joint replacement","longName":"5621715","preferredDefinition":"A surgical procedure to replace part, or all structures, of a joint with an orthopedic prosthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Joint Replacement","conceptCode":"C131579","definition":"A surgical procedure to replace part, or all structures, of a joint with an orthopedic prosthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AE87ED-ECA6-6297-E053-F662850A80DB","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-ECBF-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"ITP","valueDescription":"Idiopathic Thrombocytopenic Purpura","ValueMeaning":{"publicId":"2579903","version":"1","preferredName":"Idiopathic Thrombocytopenic Purpura","longName":"2579903","preferredDefinition":"Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Immune Thrombocytopenia","conceptCode":"C3446","definition":"Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-052C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-ECD3-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Gonadal dysfunction","valueDescription":"Gonadal Disorder","ValueMeaning":{"publicId":"5621716","version":"1","preferredName":"Gonadal Disorder","longName":"5621716","preferredDefinition":"Disease of the ovaries and testes of any etiology.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gonadal Disorder","conceptCode":"C26786","definition":"A non-neoplastic or neoplastic disorder that affects the testis or the ovary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AE87ED-ECF5-6297-E053-F662850A80DB","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-ED0E-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Adrenocortical Insufficiency","valueDescription":"Adrenocortical Insufficiency","ValueMeaning":{"publicId":"5621717","version":"1","preferredName":"Adrenocortical Insufficiency","longName":"5621717","preferredDefinition":"An endocrine or hormonal disorder that occurs when the adrenal cortex does not produce enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex (Addison's disease or primary adrenal insufficiency) or to inadequate secretion of ACTH by the pituitary gland (secondary adrenal insufficiency).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adrenocortical Insufficiency","conceptCode":"C26691","definition":"An endocrine or hormonal disorder that occurs when the adrenal cortex does not produce enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex (Addison's disease or primary adrenal insufficiency) or to inadequate secretion of ACTH by the pituitary gland (secondary adrenal insufficiency).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AE87ED-ED18-6297-E053-F662850A80DB","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"GDEEN","dateModified":"2023-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-ED31-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Avascular Necrosis","valueDescription":"Avascular Necrosis","ValueMeaning":{"publicId":"4733331","version":"1","preferredName":"Avascular Necrosis","longName":"4733331","preferredDefinition":"Tissue death resulting from an interruption to the blood supply.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Avascular Necrosis","conceptCode":"C118385","definition":"Tissue death resulting from an interruption to the blood supply.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"107C4D77-22B7-10F2-E050-BB89AD437429","latestVersionIndicator":"Yes","beginDate":"2015-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-ED45-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Bone Fracture(s)","valueDescription":"Fracture","ValueMeaning":{"publicId":"5621718","version":"1","preferredName":"Fracture","longName":"5621718","preferredDefinition":"A traumatic injury to the bone in which the continuity of the bone is broken.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fracture","conceptCode":"C3046","definition":"A traumatic injury to the bone in which the continuity of the bone is broken.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AE87ED-ED50-6297-E053-F662850A80DB","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-ED69-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Cryptogenic Organizing Pneumonia","valueDescription":"Cryptogenic Organizing Pneumonia","ValueMeaning":{"publicId":"2804712","version":"1","preferredName":"Cryptogenic Organizing Pneumonia","longName":"2804712","preferredDefinition":"A disease formerly considered a form of interstitial pneumonia. Its etiology is obscure but it may be associated with toxic fumes, infection, and connective tissue disease. Clinical symptoms include cough, dyspnea and influenza-like symptoms with the development of the usual interstitial pneumonia in many cases. Obstructive symptoms are limited to smokers. There are patchy polypoid masses of intra-alveolar granulation tissue in small airway lumina and alveolar ducts. \"Organizing\" refers to unresolved pneumonia (in which the alveolar exudate persists and eventually undergoes fibrosis) in which fibrous tissue forms in the alveoli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cryptogenic Organizing Pneumonia","conceptCode":"C62586","definition":"A form of organizing pneumonia with a non-infectious etiology. Excessive proliferation of granulation tissue occurs in alveolar ducts and alveoli and primarily causes injury to alveolar walls, but bronchioles may be affected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C7576B8-1938-1506-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-ED7E-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"DVT/PE","valueDescription":"Deep Vein Thrombosis or Pulmonary Embolism","ValueMeaning":{"publicId":"5621719","version":"1","preferredName":"Deep Vein Thrombosis or Pulmonary Embolism","longName":"5621719","preferredDefinition":"A blood clot in a deep vein, predominantly in the lower extremity, but may include the pelvis or upper extremity.: The obstruction of the pulmonary artery or one of its branches by an embolus, sometimes associated with infarction of the lung.: The coexistence of two or more disease processes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deep Vein Thrombosis","conceptCode":"C49343","definition":"A blood clot in a deep vein, predominantly in the lower extremity, but may include the pelvis or upper extremity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pulmonary Embolism","conceptCode":"C50713","definition":"The obstruction of the pulmonary artery or one of its branches by an embolus, sometimes associated with infarction of the lung.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Comorbidity","conceptCode":"C16457","definition":"The coexistence of two or more disease processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AE87ED-ED8D-6297-E053-F662850A80DB","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-EDA6-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Hemorrhagic Cystitis","valueDescription":"Hemorrhagic Cystitis","ValueMeaning":{"publicId":"5621720","version":"1","preferredName":"Hemorrhagic Cystitis","longName":"5621720","preferredDefinition":"Inflammation of the bladder resulting in bloody urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemorrhagic Cystitis","conceptCode":"C114666","definition":"Inflammation of the bladder resulting in bloody urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AE87ED-EDB2-6297-E053-F662850A80DB","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-EDCB-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Hypothyroidism","valueDescription":"Hypothyroidism","ValueMeaning":{"publicId":"2562672","version":"1","preferredName":"Hypothyroidism","longName":"2562672","preferredDefinition":"A condition in which the production of thyroid hormone by the thyroid gland is diminished. Signs and symptoms of hypothyroidism include low metabolic rate, tendency to weight gain, somnolence and sometimes myxedema. In the United States, the most common cause of hypothyroidism is Hashimoto's thyroiditis, an autoimmune disorder. SYN athyrea. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypothyroidism","conceptCode":"C26800","definition":"Abnormally low levels of thyroid hormone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C1DD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-11","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-11","modifiedBy":"COOPERM","dateModified":"2008-11-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-EDD5-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Interstitial Pneumontis or ARDS","valueDescription":"Interstitial pneumonitis or Acute Respiratory Distress Syndrome","ValueMeaning":{"publicId":"5621721","version":"1","preferredName":"Interstitial pneumonitis or Acute Respiratory Distress Syndrome","longName":"5621721","preferredDefinition":"Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Respiratory Distress Syndrome","conceptCode":"C3353","definition":"Progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery. Cases of neonatal respiratory distress syndrome are not included in this definition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AE87ED-EDE0-6297-E053-F662850A80DB","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AE87ED-EDF9-6297-E053-F662850A80DB","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Iron Overload","valueDescription":"Iron Overload","ValueMeaning":{"publicId":"2945194","version":"1","preferredName":"Iron Overload","longName":"2945194","preferredDefinition":"Accumulation of iron in the tissues. It may be a manifestation of an inherited disorder (e.g., hemochromatosis) or acquired (in patients with repeated blood transfusions). Symptoms include hepatomegaly, arthritis, diabetes mellitus, and bronzed skin. If untreated it has a progressive course and may lead to death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iron Overload","conceptCode":"C78393","definition":"Accumulation of iron in the tissues. It may be a manifestation of an inherited disorder (e.g., hemochromatosis) or acquired (in patients with repeated blood transfusions). Symptoms include hepatomegaly, arthritis, diabetes mellitus, and bronzed skin. If untreated it has a progressive course and may lead to death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"745580E8-4272-8FA9-E040-BB89AD433702","latestVersionIndicator":"Yes","beginDate":"2009-09-24","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66FF44B6-B42D-7BF3-E053-F662850A032D","beginDate":"2017-01-09","endDate":null,"createdBy":"DWARZEL","dateCreated":"2018-03-09","modifiedBy":"ONEDATA","dateModified":"2018-03-09","deletedIndicator":"No"},{"value":"Pancreatitis","valueDescription":"Pancreatitis","ValueMeaning":{"publicId":"2559694","version":"1","preferredName":"Pancreatitis","longName":"2559694","preferredDefinition":"Inflammation of the pancreas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatitis","conceptCode":"C3306","definition":"Inflammation of the pancreas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B63B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66FF44B6-B437-7BF3-E053-F662850A032D","beginDate":"2017-01-09","endDate":null,"createdBy":"DWARZEL","dateCreated":"2018-03-09","modifiedBy":"ONEDATA","dateModified":"2018-03-09","deletedIndicator":"No"},{"value":"Pulmonary Hemorrhage","valueDescription":"Pulmonary Hemorrhage","ValueMeaning":{"publicId":"5621709","version":"1","preferredName":"Pulmonary Hemorrhage","longName":"5621709","preferredDefinition":"Bleeding from the lung parenchyma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pulmonary Hemorrhage","conceptCode":"C78578","definition":"Bleeding from the lung parenchyma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AE87ED-EBB4-6297-E053-F662850A80DB","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66FF44B6-B44B-7BF3-E053-F662850A032D","beginDate":"2017-01-09","endDate":null,"createdBy":"DWARZEL","dateCreated":"2018-03-09","modifiedBy":"ONEDATA","dateModified":"2018-03-09","deletedIndicator":"No"},{"value":"Seizure","valueDescription":"Seizure","ValueMeaning":{"publicId":"5026016","version":"1","preferredName":"Seizure","longName":"5026016","preferredDefinition":"Sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Seizure","conceptCode":"C2962","definition":"Sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"20D2C91D-B832-E866-E050-BB89AD433C74","latestVersionIndicator":"Yes","beginDate":"2015-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-09-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"66FF44B6-B455-7BF3-E053-F662850A032D","beginDate":"2017-01-09","endDate":null,"createdBy":"DWARZEL","dateCreated":"2018-03-09","modifiedBy":"ONEDATA","dateModified":"2018-03-09","deletedIndicator":"No"},{"value":"Beckwith-Wiedemann","valueDescription":"Beckwith-Wiedemann Syndrome","ValueMeaning":{"publicId":"2967368","version":"1","preferredName":"Beckwith-Wiedemann Syndrome","longName":"2967368","preferredDefinition":"A genetic syndrome caused by abnormalities in chromosome 11.  It is characterized by large birth weight, macroglossia, umbilical hernia, ear abnormalities, and hypoglycemia.  Patients with this syndrome have an increased risk of developing embryonal tumors (gonadoblastoma, hepatoblastoma, Wilms tumor, Rhabdomyosarcoma) and adrenal cortex carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beckwith-Wiedemann Syndrome","conceptCode":"C34415","definition":"A genetic syndrome caused by abnormalities in chromosome 11. It is characterized by large birth weight, macroglossia, umbilical hernia, ear abnormalities, and hypoglycemia. Patients with this syndrome have an increased risk of developing embryonal tumors (gonadoblastoma, hepatoblastoma, Wilms tumor, rhabdomyosarcoma) and adrenal cortex carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7AB32307-57DC-1A4F-E040-BB89AD43618C","latestVersionIndicator":"Yes","beginDate":"2009-12-14","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-14","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5CDB-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Cirrhosis unknown etiology","valueDescription":"Unknown Etiology Cirrhosis","ValueMeaning":{"publicId":"6148977","version":"1","preferredName":"Unknown Etiology Cirrhosis","longName":"6148977","preferredDefinition":"Not known, not observed, not recorded, or refused.: The cause of a disease or abnormal condition.: A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Etiology","conceptCode":"C16390","definition":"The cause of a disease or abnormal condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cirrhosis","conceptCode":"C2951","definition":"A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6853938B-5CEA-7948-E053-F662850A1496","latestVersionIndicator":"Yes","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5D03-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Tyrosinemia","valueDescription":"Tyrosinemia","ValueMeaning":{"publicId":"6013366","version":"1","preferredName":"Tyrosinemia","longName":"6013366","preferredDefinition":"An autosomal recessive inherited metabolic disorder caused by mutations in the FAH, HPD, and TAT genes. It is characterized by deficiency of one of the enzymes that are involved in the metabolism of tyrosine. It results in elevated blood tyrosine levels and accumulation of tyrosine and its byproducts in the liver, kidney, nervous system and other organs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tyrosinemia","conceptCode":"C98640","definition":"An autosomal recessive inherited metabolic disorder caused by mutations in the FAH, HPD, and TAT genes. It is characterized by deficiency of one of the enzymes that are involved in the metabolism of tyrosine. It results in elevated blood tyrosine levels and accumulation of tyrosine and its byproducts in the liver, kidney, nervous system and other organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5CD9A0AB-573B-70DD-E053-F662850A7724","latestVersionIndicator":"Yes","beginDate":"2017-10-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-10-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5D0D-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Biliary disorder","valueDescription":"Biliary Tract Disorder","ValueMeaning":{"publicId":"3210777","version":"1","preferredName":"Biliary Tract Disorder","longName":"3210777","preferredDefinition":"A non-neoplastic or neoplastic disorder affecting the intrahepatic or extrahepatic biliary tract. Examples of non-neoplastic disorders include infection and atresia. Examples of neoplastic disorders include adenoma and carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biliary System Disorder","conceptCode":"C2899","definition":"A non-neoplastic or neoplastic disorder that affects the intrahepatic or extrahepatic bile ducts or the gallbladder. Representative examples of non-neoplastic disorders include cholangitis and cholecystitis. Representative examples of neoplastic disorders include extrahepatic bile duct adenoma, intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9DF0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5D18-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Glycogen storage disease","valueDescription":"Glycogen Storage Disease","ValueMeaning":{"publicId":"2593481","version":"1","preferredName":"Glycogen Storage Disease","longName":"2593481","preferredDefinition":"An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glycogen Storage Disease","conceptCode":"C61272","definition":"An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BD3AD6-BCD6-64E1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5D23-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Alpha-1 antitrypsin","valueDescription":"Alpha-1 Antitrypsin Deficiency","ValueMeaning":{"publicId":"3171840","version":"1","preferredName":"Alpha-1 Antitrypsin Deficiency","longName":"3171840","preferredDefinition":"A genetic disorder characterized by decreased alpha-1 antitrypsin activity in the lungs and blood and deposition of alpha-1 antitrypsin protein in the hepatocytes. These abnormalities result from defective production of alpha-1 antitrypsin and lead to the development of emphysema, cirrhosis, and liver failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha-1 Antitrypsin Deficiency","conceptCode":"C84397","definition":"A genetic disorder characterized by decreased alpha-1 antitrypsin activity in the lungs and blood and deposition of alpha-1 antitrypsin protein in the hepatocytes. These abnormalities result from defective production of alpha-1 antitrypsin and lead to the development of emphysema, cirrhosis, and liver failure.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97DDA7EA-0146-07E7-E040-BB89AD4351C6","latestVersionIndicator":"Yes","beginDate":"2010-12-20","endDate":null,"createdBy":"WHITES","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5D2E-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Adenocarcinoma","valueDescription":"Adenocarcinoma","ValueMeaning":{"publicId":"2831117","version":"1","preferredName":"Adenocarcinoma","longName":"2831117","preferredDefinition":"carcinoma derived from glandular tissue or in which tumor cells form recognizable glandular structures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"61F598EF-7D06-BDE9-E040-BB89AD43552F","latestVersionIndicator":"Yes","beginDate":"2009-02-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5D39-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Neuroendocrine tumor","valueDescription":"Neuroendocrine Neoplasm","ValueMeaning":{"publicId":"3211298","version":"1","preferredName":"Neuroendocrine Neoplasm","longName":"3211298","preferredDefinition":"A benign or malignant neoplasm composed of cells of neuroendocrine origin.  Representative examples include paraganglioma, carcinoid tumor, and neuroendocrine carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroendocrine Neoplasm","conceptCode":"C3809","definition":"An epithelial neoplasm with neuroendocrine differentiation. This category includes neuroendocrine tumors, neuroendocrine carcinomas, and paragangliomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EA11-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5D4E-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Intraductal papillary mucinous neoplasm","valueDescription":"Pancreatic Intraductal Papillary-Mucinous Carcinoma","ValueMeaning":{"publicId":"2581794","version":"1","preferredName":"Pancreatic Intraductal Papillary-Mucinous Carcinoma","longName":"2581794v1.00","preferredDefinition":"A malignant glandular neoplasm arising from the exocrine pancreas. Microscopically it is characterized by the presence of mucoid stroma formation, papillary patterns, and cystic changes. It has been associated with KRAS and Tp53 gene mutations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Intraductal Papillary-Mucinous Carcinoma","conceptCode":"C5725","definition":"A malignant glandular neoplasm arising from the exocrine pancreas. Microscopically it is characterized by the presence of mucoid stroma formation, papillary patterns, and cystic changes. It has been associated with KRAS and Tp53 gene mutations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C8F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-10","modifiedBy":"KUMMEROA","dateModified":"2023-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5D63-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"H. pylori infection","valueDescription":"Helicobacter Pylori Infection","ValueMeaning":{"publicId":"6148978","version":"1","preferredName":"Helicobacter Pylori Infection","longName":"6148978","preferredDefinition":"A bacterial infection of the stomach, caused by Helicobacter pylori.  It is associated with the development of peptic ulcer and mucosa-associated lymphoid tissue lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Helicobacter Pylori Infection","conceptCode":"C39293","definition":"A bacterial infection of the stomach, caused by Helicobacter pylori.  It is associated with the development of peptic ulcer and mucosa-associated lymphoid tissue lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6853938B-5D6E-7948-E053-F662850A1496","latestVersionIndicator":"Yes","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5D87-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Barrett's Esophagus","valueDescription":"Barrett Esophagus","ValueMeaning":{"publicId":"3210773","version":"1","preferredName":"Barrett Esophagus","longName":"3210773","preferredDefinition":"Esophageal segment lined with columnar metaplastic epithelium which is flat or villiform.  Barrett's epithelium is characterized by two different types of cells: goblet cells and columnar cells.  The symptomatology of Barrett's esophagus is that of gastro-esophageal reflux.  It is the precursor of most esophageal adenocarcinomas.  (WHO, 2000) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Barrett Esophagus","conceptCode":"C2891","definition":"Esophageal lesion lined with columnar metaplastic epithelium which is flat or villiform. Barrett epithelium is characterized by two different types of cells: goblet cells and columnar cells. The symptomatology of Barrett esophagus is that of gastro-esophageal reflux. It is the precursor of most esophageal adenocarcinomas.  (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9D5E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5D9B-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Colon polyps","valueDescription":"Colon Polyp","ValueMeaning":{"publicId":"4827926","version":"1","preferredName":"Colon Polyp","longName":"4827926","preferredDefinition":"A polypoid lesion that arises from the colon and protrudes into the lumen.  This group includes adenomatous polyps, serrated polyps, and hamartomatous polyps.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colon Polyp","conceptCode":"C2954","definition":"A polypoid lesion that arises from the colon and protrudes into the lumen.  This group includes adenomatous polyps, serrated polyps, and hamartomatous polyps.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"166470EB-F37E-9810-E050-BB89AD4311C9","latestVersionIndicator":"Yes","beginDate":"2015-05-18","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-05-18","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5DA6-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Diabetes, NOS","valueDescription":"Not Otherwise Specified Diabetes Mellitus","ValueMeaning":{"publicId":"6148979","version":"1","preferredName":"Not Otherwise Specified Diabetes Mellitus","longName":"6148979","preferredDefinition":"Not characterized in any other way.: A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Diabetes Mellitus","conceptCode":"C2985","definition":"A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6853938B-5DB4-7948-E053-F662850A1496","latestVersionIndicator":"Yes","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5DCD-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Fanconi anemia","valueDescription":"Fanconi Anemia","ValueMeaning":{"publicId":"5651022","version":"1","preferredName":"Fanconi Anemia","longName":"5651022","preferredDefinition":"A rare inherited disorder in which the bone marrow does not make blood cells. It is usually diagnosed in children between 2 and 15 years old. Symptoms include frequent infections, easy bleeding, and extreme tiredness. People with Fanconi anemia may have a small skeleton and brown spots on the skin. They also have an increased risk of developing certain types of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fanconi Anemia","conceptCode":"C62505","definition":"An autosomal recessive genetic disorder characterized by bone marrow failure, skeletal abnormalities, and an increased incidence of the development of neoplasias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"479020AD-0CB9-3909-E053-F662850A62CA","latestVersionIndicator":"Yes","beginDate":"2017-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-02-02","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5DD7-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Rubinstein-Taybi syndrome","valueDescription":"Rubinstein-Taybi Syndrome","ValueMeaning":{"publicId":"3211427","version":"1","preferredName":"Rubinstein-Taybi Syndrome","longName":"3211427","preferredDefinition":"A rare genetic syndrome mapped to chromosome 16p13.3 and associated with mutations in the CREBBP gene.  It is characterized by mental and growth retardation, distinctive facial features (prominent nose, low-set ears, microcephaly, and small mouth), and broad thumbs and great toes.  Patients are at an increased risk of developing benign and malignant neoplasms, including nervous system neoplasms and malignant lymphoproliferative disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rubinstein-Taybi Syndrome","conceptCode":"C75466","definition":"A rare genetic syndrome mapped to chromosome 16p13.3 and associated with mutations in the CREBBP gene. It is characterized by mental and growth retardation, distinctive facial features (prominent nose, low-set ears, microcephaly, and small mouth), and broad thumbs and great toes. Patients are at an increased risk of developing benign and malignant neoplasms, including nervous system neoplasms and malignant lymphoproliferative disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FC39-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5DF8-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Li-Fraumeni syndrome","valueDescription":"Li-Fraumeni Syndrome","ValueMeaning":{"publicId":"3211225","version":"1","preferredName":"Li-Fraumeni Syndrome","longName":"3211225","preferredDefinition":"An autosomal dominant hereditary neoplastic syndrome caused by an alteration in the p53 tumor suppressor gene.  It is characterized by the development of malignant neoplasms at various anatomic sites.  The malignant neoplasms associated with Li-Fraumeni syndrome include adrenal cortex carcinoma, astrocytic tumors, colorectal carcinoma, gastric carcinoma, malignant breast neoplasms, medulloblastoma, osteosarcoma, and soft tissue sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Li-Fraumeni Syndrome","conceptCode":"C3476","definition":"An autosomal dominant cancer predisposition syndrome caused by germline mutations of the TP53 gene. It is associated with breast carcinoma, choroid plexus carcinoma, adrenal cortex carcinoma, astrocytic tumors, medulloblastoma, soft tissue sarcoma, osteosarcoma, and leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DF6B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5DE2-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Gorlin syndrome","valueDescription":"Nevoid Basal Cell Carcinoma Syndrome","ValueMeaning":{"publicId":"3210902","version":"1","preferredName":"Nevoid Basal Cell Carcinoma Syndrome","longName":"3210902","preferredDefinition":"An autosomal dominant genetic syndrome caused by abnormalities in the PTCH gene.  It is characterized by multiple basal cell carcinomas at a young age, odontogenic keratocysts, and skeletal defects (bifurcated and splayed ribs, fusion of vertebrae, spinal bifida).  Patients with this syndrome may also develop medulloblastomas and ovarian fibromas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nevoid Basal Cell Carcinoma Syndrome","conceptCode":"C2892","definition":"An autosomal dominant genetic syndrome caused by abnormalities in the PTCH and SUFU gene. It is characterized by multiple basal cell carcinomas at a young age, odontogenic keratocysts, and skeletal defects (bifurcated and splayed ribs, fusion of vertebrae, spinal bifida). Patients with this syndrome may also develop medulloblastomas and ovarian fibromas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B1D8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5DED-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Turcot syndrome","valueDescription":"Turcot Syndrome","ValueMeaning":{"publicId":"6002212","version":"1","preferredName":"Turcot Syndrome","longName":"6002212","preferredDefinition":"An autosomal dominant hereditary neoplastic syndrome caused by mutations in the PMS2, MLH1, MSH2, or APC genes. There are two types described, type 1, characterized by the presence of glioblastoma and often associated with hereditary nonpolyposis colorectal carcinoma, and type 2, characterized by the presence of medulloblastoma and familiar adenomatous polyposis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Turcot Syndrome","conceptCode":"C3938","definition":"An autosomal dominant hereditary neoplastic syndrome caused by mutations in the PMS2, MLH1, MSH2, or APC genes. There are two types described, type 1, characterized by the presence of glioblastoma and often associated with hereditary nonpolyposis colorectal carcinoma, and type 2, characterized by the presence of medulloblastoma and familiar adenomatous polyposis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B4E1CD4-4E37-160D-E053-F662850A7005","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5E03-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Familial Adenomatous Polyposis","valueDescription":"Adenomatous Polyposis Coli","ValueMeaning":{"publicId":"2577526","version":"1","preferredName":"Adenomatous Polyposis Coli","longName":"2577526","preferredDefinition":"An autosomal dominant disorder, characterized by the presence of multiple adenomas in the colon and rectum. It is caused by a germline mutation in the adenomatous polyposis coli (APC) gene which is located on the long arm of chromosome 5. The adenomas are most often tubular, and they have the tendency to progress to adenocarcinoma. They can occur throughout the colon, but they tend to concentrate in the rectum and sigmoid colon. The colorectal adenomas are detected during endoscopic examination between the age of 10 and 20 years. The adenomas increase in size and numbers with age, and there is usually progression of one or more adenomas to adenocarcinoma. The mean age of development of adenocarcinoma is about 40 years. Signs include rectal bleeding and mucousy diarrhea.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Familial Adenomatous Polyposis","conceptCode":"C3339","definition":"An autosomal dominant disorder, characterized by the presence of multiple adenomas in the colon and rectum. It is caused by a germline mutation in the adenomatous polyposis coli (APC) gene which is located on the long arm of chromosome 5. The adenomas are most often tubular, and they have the tendency to progress to adenocarcinoma. They can occur throughout the colon, but they tend to concentrate in the rectum and sigmoid colon. The colorectal adenomas are detected during endoscopic examination between the age of 10 and 20 years. The adenomas increase in size and numbers with age, and there is usually progression of one or more adenomas to adenocarcinoma. The mean age of development of adenocarcinoma is about 40 years. Signs include rectal bleeding and mucousy diarrhea.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FBE3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-01-28","modifiedBy":"COOPERM","dateModified":"2018-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5E18-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Lynch Syndrome","valueDescription":"Hereditary Non-Polyposis Colon Cancer","ValueMeaning":{"publicId":"2716424","version":"1","preferredName":"Hereditary Non-Polyposis Colon Cancer","longName":"2716424","preferredDefinition":"An autosomal dominant hereditary neoplastic syndrome characterized by the development of colorectal carcinoma and a high risk of developing endometrial carcinoma, gastric carcinoma, ovarian carcinoma, renal pelvis carcinoma, and small intestinal carcinoma.  Patients often develop colorectal carcinomas at an early age (mean, 45 years).  In the majority of the cases the lesions arise from the proximal colon.  At the molecular level, high-frequency microsatellite instability is present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lynch Syndrome","conceptCode":"C8494","definition":"An autosomal dominant hereditary neoplastic syndrome characterized by the development of colorectal carcinoma and a high risk of developing endometrial carcinoma, gastric carcinoma, ovarian carcinoma, renal pelvis carcinoma, and small intestinal carcinoma. Patients often develop colorectal carcinomas at an early age (mean, 45 years). In the majority of the cases the lesions arise from the proximal colon. At the molecular level, high-frequency microsatellite instability is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41B659B0-44F3-5521-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2007-12-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5E2D-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Diabetes, type II","valueDescription":"Type 2 Diabetes Mellitus","ValueMeaning":{"publicId":"2976115","version":"1","preferredName":"Type 2 Diabetes Mellitus","longName":"2976115","preferredDefinition":"A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type 2 Diabetes Mellitus","conceptCode":"C26747","definition":"A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C59A54D-BA0C-5B26-E040-BB89AD432407","latestVersionIndicator":"Yes","beginDate":"2010-01-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-01-04","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5E38-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Peutz-Jeghers Syndrome","valueDescription":"Peutz-Jeghers Syndrome","ValueMeaning":{"publicId":"3211359","version":"1","preferredName":"Peutz-Jeghers Syndrome","longName":"3211359","preferredDefinition":"An inherited condition characterized by generalized hamartomatous multiple polyposis of the intestinal tract. Transmitted in an autosomal dominant fashion, Peutz-Jeghers syndrome consistently involves the jejunum and is associated with melanin spots of the lips, buccal mucosa, and fingers. This syndrome is associated with abnormalities of chromosome 19. Also known as Jeghers-Peutz syndrome and Peutz's syndrome. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peutz-Jeghers Syndrome","conceptCode":"C3324","definition":"An inherited condition characterized by generalized hamartomatous multiple polyposis of the intestinal tract. Transmitted in an autosomal dominant fashion, Peutz-Jeghers syndrome consistently involves the jejunum and is associated with melanin spots of the lips, buccal mucosa, and fingers. This syndrome is associated with abnormalities of chromosome 19. Also known as Jeghers-Peutz syndrome and Peutz's syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F2D3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5E43-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Crohn Disease","valueDescription":"Crohn Disease","ValueMeaning":{"publicId":"4618015","version":"1","preferredName":"Crohn Disease","longName":"4618015","preferredDefinition":"A chronic, transmural inflammation that can affect any location along the gastrointestinal tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crohn Disease","conceptCode":"C2965","definition":"A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09518164-CF0E-8FD3-E050-BB89AD433831","latestVersionIndicator":"Yes","beginDate":"2014-12-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-12-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5E58-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Celiac Disease","valueDescription":"Celiac Disease","ValueMeaning":{"publicId":"3249580","version":"1","preferredName":"Celiac Disease","longName":"3249580","preferredDefinition":"A digestive disease that is caused by an immune response to a protein called gluten, which is found in wheat, rye, barley, and oats. Celiac disease damages the lining of the small intestine and interferes with the absorption of nutrients from food. A person with celiac disease may become malnourished no matter how much food is consumed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Celiac Disease","conceptCode":"C26714","definition":"An autoimmune genetic disorder with an unknown pattern of inheritance that primarily affects the digestive tract. It is caused by intolerance to dietary gluten. Consumption of gluten protein triggers an immune response which damages small intestinal villi and prevents adequate absorption of nutrients. Clinical signs include abdominal cramping, diarrhea or constipation and weight loss. If untreated, the clinical course may progress to malnutrition, anemia, osteoporosis and an increased risk of intestinal malignancies. However, the prognosis is favorable with successful avoidance of gluten in the diet.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6D99025-BE2B-DBB4-E040-BB89AD434418","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6853938B-5E6D-7948-E053-F662850A1496","beginDate":"2018-03-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-26","modifiedBy":"ONEDATA","dateModified":"2018-03-26","deletedIndicator":"No"},{"value":"Clonal hematopoiesis","valueDescription":"Age-Related Clonal Hematopoiesis","ValueMeaning":{"publicId":"6731055","version":"1","preferredName":"Age-Related Clonal Hematopoiesis","longName":"6731055","preferredDefinition":"The gradual, clonal expansion of hematopoietic stem and progenitor cells carrying specific, disruptive, and recurrent genetic variants, in individuals without clear diagnosis of hematological malignancies. It is associated with an increased risk of developing hematologic cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Age-Related Clonal Hematopoiesis","conceptCode":"C155821","definition":"The gradual, clonal expansion of hematopoietic stem and progenitor cells carrying specific, disruptive, and recurrent genetic variants, in individuals without clear diagnosis of hematological malignancies. It is associated with an increased risk of developing hematologic cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8762E624-F048-5448-E053-F662850A970F","latestVersionIndicator":"Yes","beginDate":"2019-04-25","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-25","modifiedBy":"ONEDATA","dateModified":"2019-04-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8762E624-F061-5448-E053-F662850A970F","beginDate":"2019-04-25","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-25","modifiedBy":"ONEDATA","dateModified":"2019-04-25","deletedIndicator":"No"},{"value":"HIV","valueDescription":"Human Immunodeficiency Virus","ValueMeaning":{"publicId":"4395759","version":"1","preferredName":"Human Immunodeficiency Virus","longName":"4395759","preferredDefinition":"Human immunodeficiency virus. Species of LENTIVIRUS, subgenus primate lentiviruses (LENTIVIRUSES, PRIMATE), formerly designated T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). It is acknowledged to be the agent responsible for the acute infectious manifestations, neurologic disorders, and immunologic abnormalities linked to the ACQUIRED IMMUNODEFICIENCY SYNDROME.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Immunodeficiency Virus","conceptCode":"C14219","definition":"The virus isolated and recognized as the etiologic agent of AIDS. HIV-1 is classified as a lentivirus, a subtype of retroviruses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEB8F754-D7D1-8D06-E040-BB89AD437F49","latestVersionIndicator":"Yes","beginDate":"2014-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8762E624-F075-5448-E053-F662850A970F","beginDate":"2019-04-25","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-25","modifiedBy":"ONEDATA","dateModified":"2019-04-25","deletedIndicator":"No"},{"value":"Fibromyalgia","valueDescription":"Fibromyalgia","ValueMeaning":{"publicId":"3249543","version":"1","preferredName":"Fibromyalgia","longName":"3249543","preferredDefinition":"A chronic disorder of unknown etiology charaterized by pain, stiffness, and tenderness in the muscles of the neck, shoulders, back, hips, arms, and legs  Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibromyalgia","conceptCode":"C87497","definition":"A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6D8A436-0825-647C-E040-BB89AD435D86","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8762E624-F08A-5448-E053-F662850A970F","beginDate":"2019-04-25","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-25","modifiedBy":"ONEDATA","dateModified":"2019-04-25","deletedIndicator":"No"},{"value":"Chronic fatigue syndrome","valueDescription":"Chronic Fatigue Syndrome","ValueMeaning":{"publicId":"6731057","version":"1","preferredName":"Chronic Fatigue Syndrome","longName":"6731057","preferredDefinition":"A syndrome of unknown etiology. Chronic fatigue syndrome (CFS) is a clinical diagnosis characterized by an unexplained persistent or relapsing chronic fatigue that is of at least six months' duration, is not the result of ongoing exertion, is not substantially alleviated by rest, and results in substantial reduction of previous levels of occupational, educational, social, or personal activities. Common concurrent symptoms of at least six months duration include impairment of memory or concentration, diffuse pain, sore throat, tender lymph nodes, headaches of a new type, pattern, or severity, and nonrestorative sleep. The etiology of CFS may be viral or immunologic. Neurasthenia and fibromyalgia may represent related disorders. Also known as myalgic encephalomyelitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Fatigue Syndrome","conceptCode":"C3037","definition":"A syndrome of unknown etiology. Chronic fatigue syndrome (CFS) is a clinical diagnosis characterized by an unexplained persistent or relapsing chronic fatigue that is of at least six months' duration, is not the result of ongoing exertion, is not substantially alleviated by rest, and results in substantial reduction of previous levels of occupational, educational, social, or personal activities. Common concurrent symptoms of at least six months duration include impairment of memory or concentration, diffuse pain, sore throat, tender lymph nodes, headaches of a new type, pattern, or severity, and nonrestorative sleep. The etiology of CFS may be viral or immunologic. Neurasthenia and fibromyalgia may represent related disorders. Also known as myalgic encephalomyelitis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8762E624-F098-5448-E053-F662850A970F","latestVersionIndicator":"Yes","beginDate":"2019-04-25","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-25","modifiedBy":"ONEDATA","dateModified":"2019-04-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8762E624-F0B1-5448-E053-F662850A970F","beginDate":"2019-04-25","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-25","modifiedBy":"ONEDATA","dateModified":"2019-04-25","deletedIndicator":"No"},{"value":"AIDS","valueDescription":"Acquired Immunodeficiency Syndrome","ValueMeaning":{"publicId":"3105388","version":"1","preferredName":"Acquired Immunodeficiency Syndrome","longName":"3105388","preferredDefinition":"A syndrome resulting from the acquired deficiency of cellular immunity caused by the human immunodeficiency virus (HIV). It is characterized by the reduction of the Helper T-lymphocytes in the peripheral blood and the lymph nodes; opportunistic infections (usually pneumocystis carinii pneumonia, cytomegalovirus (CMV) infections, tuberculosis, candida infections, and cryptococcosis); and the development of malignant neoplasms (usually non-Hodgkin's lymphoma and Kaposi's sarcoma). The human immunodeficiency virus is transmitted through sexual contact, sharing of contaminated needles, or transfusion of contaminated blood. Generalized lymphadenopathy, fever, weight loss, and chronic diarrhea are common symptoms of AIDS. The patients usually die either of opportunistic infections or malignant neoplasms. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acquired Immunodeficiency Syndrome","conceptCode":"C2851","definition":"A syndrome resulting from the acquired deficiency of cellular immunity caused by the human immunodeficiency virus (HIV). It is characterized by the reduction of the Helper T-lymphocytes in the peripheral blood and the lymph nodes. Symptoms include generalized lymphadenopathy, fever, weight loss, and chronic diarrhea. Patients with AIDS are especially susceptible to opportunistic infections, tuberculosis, candida infections, and cryptococcosis), and the development of malignant neoplasms (usually non-Hodgkin lymphoma and Kaposi sarcoma). The human immunodeficiency virus is transmitted through sexual contact, sharing of contaminated needles, or transfusion of contaminated blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"88262FC2-CEBC-A44E-E040-BB89AD435306","latestVersionIndicator":"Yes","beginDate":"2010-06-03","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-03","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DCF48206-5631-3204-E053-4EBD850AE4C4","beginDate":"2022-04-18","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-04-18","modifiedBy":"ONEDATA","dateModified":"2022-04-18","deletedIndicator":"No"},{"value":"Hemiplegia","valueDescription":"Hemiplegia","ValueMeaning":{"publicId":"8172574","version":"1","preferredName":"Hemiplegia","longName":"8172574","preferredDefinition":"Paralysis of one side of the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemiplegia","conceptCode":"C64329","definition":"Paralysis of one side of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCF48206-563E-3204-E053-4EBD850AE4C4","latestVersionIndicator":"Yes","beginDate":"2022-04-18","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-04-18","modifiedBy":"ONEDATA","dateModified":"2022-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DCF48206-5657-3204-E053-4EBD850AE4C4","beginDate":"2022-04-18","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-04-18","modifiedBy":"ONEDATA","dateModified":"2022-04-18","deletedIndicator":"No"},{"value":"Dementia","valueDescription":"Dementia","ValueMeaning":{"publicId":"3165569","version":"1","preferredName":"Dementia","longName":"3165569","preferredDefinition":"An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dementia","conceptCode":"C4786","definition":"Loss of intellectual abilities interfering with an individual's social and occupational functions. Causes include Alzheimer's disease, brain injuries, brain tumors, and vascular disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96FCF74F-C196-EAB7-E040-BB89AD437850","latestVersionIndicator":"Yes","beginDate":"2010-12-09","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DCF48206-5661-3204-E053-4EBD850AE4C4","beginDate":"2022-04-18","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-04-18","modifiedBy":"ONEDATA","dateModified":"2022-04-18","deletedIndicator":"No"},{"value":"TIA","valueDescription":"Transient Ischemic Attack","ValueMeaning":{"publicId":"2944400","version":"1","preferredName":"Transient Ischemic Attack","longName":"2944400","preferredDefinition":"A brief attack (from a few minutes to an hour) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transient Ischemic Attack","conceptCode":"C50781","definition":"A brief attack (from a few minutes to an hour) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7431FEA7-FCE7-A5C9-E040-BB89AD4324B4","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-22","modifiedBy":"ONEDATA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DCF48206-566C-3204-E053-4EBD850AE4C4","beginDate":"2022-04-18","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-04-18","modifiedBy":"ONEDATA","dateModified":"2022-04-18","deletedIndicator":"No"},{"value":"CVA or TIA","valueDescription":null,"ValueMeaning":{"publicId":"14506029","version":"1","preferredName":"Has a Cerebrovascular Accident or Transient Ischemic Disease","longName":"14506029v1.00","preferredDefinition":"A question about whether an individual has or had a cerebrovascular accident or transient ischemic disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Has a Cerebrovascular Accident or Transient Ischemic Disease","conceptCode":"C106378","definition":"A question about whether an individual has or had a cerebrovascular accident or transient ischemic disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05F5F43F-E5D7-1389-E063-731AD00AB287","latestVersionIndicator":"Yes","beginDate":"2023-09-22","endDate":null,"createdBy":"BMAESKE","dateCreated":"2023-09-22","modifiedBy":"BMAESKE","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05F5F43F-E5D8-1389-E063-731AD00AB287","beginDate":"2023-09-22","endDate":null,"createdBy":"BMAESKE","dateCreated":"2023-09-22","modifiedBy":"BMAESKE","dateModified":"2023-09-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2970662","version":"1","preferredName":"Comorbidity Condition Name","preferredDefinition":"The coexistence of two or more disease processes.:A state of being, such as a state of health.:The words or language units by which a thing is known.","longName":"C16457:C25457:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Comorbidity","conceptCode":"C16457","definition":"The coexistence of two or more disease processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Condition","conceptCode":"C25457","definition":"A state of being, such as a state of health.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B026653-DA2A-DD0C-E040-BB89AD4324C4","latestVersionIndicator":"Yes","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-18","modifiedBy":"ONEDATA","dateModified":"2009-12-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B026653-DA3B-DD0C-E040-BB89AD4324C4","latestVersionIndicator":"Yes","beginDate":"2009-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-18","modifiedBy":"BMAESKE","dateModified":"2023-09-22","changeDescription":"03-09-2018 Remove space at the end of 4 PVs DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"ABNL_ELIG_COMBID_NM","type":"USED_BY","context":"DCP"}],"ReferenceDocuments":[{"name":"If the patient did not meet t","type":"Preferred Question Text","description":"If the patient did not meet trial eligibility criteria related to concurrent disease/condition, indicate the disease/condition that prohibited eligibility","url":null,"context":"DCP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B5BD529-8AF0-231B-E050-BB89AD430541","latestVersionIndicator":"Yes","beginDate":"2016-02-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-09","modifiedBy":"ZHANGWE","dateModified":"2019-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}